Imagine growing medicines inside plants the way farmers grow crops — except instead of tomatoes, you harvest proteins that treat diseases like rheumatoid arthritis or neutralize HIV. Pharma-Factory brought together 5 biotech SMEs and 9 academic partners to turn six different plant-based "mini-factories" (whole plants, algae, plant cell cultures) into reliable production lines for drugs, vaccines, and diagnostic kits. Two products actually made it to market: a recombinant protein kit and a diagnostic kit for a hard-to-detect form of rheumatoid arthritis. The whole idea is that plants can manufacture complex biological medicines cheaper and faster than traditional steel-tank bioreactors.
Producing biological medicines, vaccines, and diagnostic reagents using traditional mammalian cell cultures or bacterial fermentation is expensive, slow to scale, and requires heavy infrastructure. For SMEs and mid-size biotech companies, these barriers can make it impossible to bring new bioproducts to market competitively. There is a growing need for cheaper, more flexible manufacturing alternatives that can produce complex proteins at commercial quality.
The project delivered 2 marketed products: a recombinant protein kit and a diagnostic kit for sero-negative rheumatoid arthritis. It also advanced 6 plant-based manufacturing platforms (whole plants, algae, hairy roots, plant cell culture) to TRL 5, along with new synthetic biology tools, regulatory pathway maps for each platform, techno-economic evaluations, and life cycle analyses.
If you are a biotech company struggling with the high cost and complexity of mammalian cell culture for producing recombinant proteins — this project developed 6 plant-based manufacturing platforms that reached TRL 5, with a recombinant protein kit already placed on the market. Plant molecular farming can cut production costs and scale more flexibly than traditional bioreactors.
If you are an aquaculture health company looking for cost-effective vaccine production — this project developed a vaccine candidate for infectious spleen and kidney necrosis virus (ISKNV) in fish using plant-based expression systems. With 5 SMEs driving the product pipeline and TRL 5 achieved across platforms, the technology is validated for scaling toward commercial veterinary products.
If you are a diagnostics company needing affordable production of antibodies or antigens for test kits — this project brought a diagnostic kit for sero-negative rheumatoid arthritis to market using plant-produced reagents. Plant-based production of diagnostic components can reduce manufacturing costs while maintaining the quality needed for clinical use.
The project conducted techno-economic evaluations and life cycle analyses for each of the 6 platforms, but specific cost figures are not published in the available data. What is clear is that plant molecular farming was designed to increase competitiveness of European bio-industry by resolving economic bottlenecks. Contact the consortium for detailed cost comparisons.
The project advanced 6 different plant molecular farming platforms — whole plants, algae, hairy roots, and plant cell culture — each with specific manufacturing advantages. All platforms reached Technology Readiness Level 5 within the project lifetime. Two products were commercialized, demonstrating that the path from lab to market is viable.
The consortium includes 5 SMEs that developed specific products, so IP likely sits with those companies. With 14 partners across 7 countries, licensing arrangements would need to be negotiated with the relevant SME or academic partner holding rights to the specific platform or product of interest.
A dedicated regulatory work package identified a clear regulatory path for each of the 6 platform technologies. Two products reached market (a recombinant protein kit and a diagnostic kit for sero-negative RA), indicating that at least those products cleared the necessary regulatory hurdles.
The project ran from 2017 to 2022, during which 2 products went from development to market. The platforms are at TRL 5, meaning new products using these established platforms could potentially reach market faster than starting from scratch, though timelines depend on the specific product and its regulatory requirements.
The 6 platforms range from whole plants to algae and plant cell cultures, each requiring different infrastructure. The project developed new synthetic biology tools to increase the competitiveness, utility and versatility of each platform. Integration feasibility depends on which platform suits your product — some (like plant cell culture) may fit more easily into existing biomanufacturing setups.
The project closed in August 2022, but the 5 SME partners are commercially active companies. The project website (pharmafactory.org) and coordinator at St George's Hospital Medical School in the UK can provide current contact information for the relevant partners.
This is a commercially serious consortium with 14 partners across 7 countries, featuring a strong 36% industry ratio with 5 industrial partners including 3 SMEs. The balance of 5 universities and 4 research organizations backing 5 product-developing SMEs shows a pipeline designed to move science into business. The coordinator is St George's Hospital Medical School in the UK, a respected medical institution, which adds clinical credibility. The geographic spread across Germany, Spain, Finland, France, Israel, Italy, and the UK covers major European biotech hubs. The fact that SMEs conceived and designed the project — rather than academics — signals genuine commercial intent, which is confirmed by 2 products reaching market.
St George's Hospital Medical School, London, UK — reach out via the project website or university directory
Want an introduction to the Pharma-Factory team for licensing or partnership? SciTransfer can connect you with the right partner for your specific product needs.
